Photodynamic molecular beacon (PMB) is a novel photodynamic therapy (PDT) concept featuring the precise control of the ability of photosensitizer (PS) to produce singlet oxygen in response to specific cancer-associated biomarkers. It comprises a disease-specific linker, a PS and a singlet oxygen quencher so that the PS's photodynamic toxicity is silenced until the linker interacts with a tumor-associated biomarker. The development of PMB depends on two key factors. The first is the design of a suitable PS-quencher pair to achieve an effective singlet oxygen quenching, minimizing phototoxicity of native PMB in non-targeted (normal) cells. The second is the design of a suitable linker for the choice of target biomarker to achieve a specific photodynamic activation, resulting in selective PDT efficacy in targeted (tumor) cells. These two factors make PMB designs versatile and customizable. In this report, we will focus on the new directions on PMB linker design utilizing two "on-and-off" activation mechanisms. The first one uses a "cleavable" linker that is triggered by fibroblast activation protein or phospholipase. The second one uses an "openable" linker that can hybridize with a tumor-specific mRNA.
INTRODUCTION
Photodynamic therapy (PDT) is a cancer treatment modality involving the combination of light, a photosensitizer (PS) and molecular oxygen. Each factor is ineffective by itself, but when the PS is irradiated with light of an appropriate wavelength in the presence of oxygen, cytotoxic reactive oxygen species, mainly singlet oxygen ( 1 O 2 ), are produced. We recently introduced a new concept, 'photodynamic molecular beacons (PMB)' featuring the precise control of the ability of PS to produce 1 O 2 by responding to specific cancer-associated biomarker 1, 2 .Briefly, this PMB comprises a disease-specific peptide linker, a PS and a 1 O 2 quencher so that the PS's photodynamic toxicity is silenced until the peptide linker is cleaved by a tumor-associated biomarker. Thus, the PDT selectivity will no longer solely depend on how selectively the PS can be delivered to cancer cells. Rather, it will depend on how completely the PMB photoactivity is silenced in non-targeted (normal) cells and how selectively the PMB linker interacts with the choice of the biomarker in targeted cancer cells.
The silencing of PMB photoactivity in non-targeted cells lies on its 1 O 2 quenching efficiency. Since 1 O 2 is produced by energy transfer from the triplet state of a PS, generated by an intersystem crossing from the PS excited singlet state, 1 O 2 quenching could be potentially achieved by: 1) direct scavenging 1 O 2 , 2) quenching PS triplet excited state and 3) quenching PS singlet excited state. The overall quenching efficiency of PMB is dictated by the choice of PS-quencher pairs, depending on their individual photoproperties, 1 O 2 quenching mode, and their spatial distance through the choice of linkers. In our previous studies, by using short peptide sequences (8) (9) (10) (11) On the other hand, the linker design also dictates the ultimate PDT selectivity of PMB in targetedtumor cells. With the increasing knowledge about the human genome in health and disease, various biomolecules were discovered as tumor-specific biomarkers, thus the selection of a specific target biomarker and the design of its corresponding linker are two key issues for the PMB activation. So far we have developed two different "on-and-off" activation mechanisms to make the PMB switchable. As depicted in Figure 1 , a PS and a quencher are conjugated in PMB via a linker molecule and are initially kept in close proximity. When the PMB meet the target biomarker, the linker could be either cleaved or opened, and hence the quencher will be removed from the close proximity of the PS, making the PS photodynamic active. Upon the light irradiation, 1 O 2 will be generated to destroy the targeted cells. Based on these activation mechanisms, we introduce here three different linkers design for targeting fibroblast activation protein (FAP), phospholipases and c-raf-1 mRNA respectively.
MATERIALS AND METHODS
UV-vis and fluorescence spectra were recorded on a Perkin-Elmer (Boston, MA, USA) Lambda 20 spectrophotometer and LS-50B spectrofluorometer, respectively. MALDI-TOF mass spectroscopy was performed on an Applied Biosystems (Foster City, CA, USA) Voyager DE system using CHCA matrix. Reverse phase (RP) analytical HPLC was performed on a Zorbax 300SB-C3 column using a Waters 600 Controller with a 2996 photodiode array detector ( HPLC method: Solvent A= 0.1% TFA/Water; Solvent B= Acetonitrile; Gradient: from 90% of A and 10% of B to 100% of B over 45min; flow rate:1.5mL/min). Synthesis of FAP-triggered PMB (1) Pyro-TSGPNQEQK(BHQ3) (FAP-PPB) (Figure 2A )
The peptide synthesis reagents for activation, 1-hydroxybenzotriazole (HOBt) and O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HBTU), were purchased from ACROS (Morris Plains, NJ) and Sigma-Aldrich (St. Louis, MO), respectively. The Sieber amide resins and all of the N-α-Fmoc protected amino acids were purchased from Novabiochem (San Diego, CA).
Fmoc-T(Trt)S(Trt)GPNQE(O-2-PhiPr)QK(Mtt)-Sieber resin(1)
A peptide of Fmoc-T(Trt)S(Trt)GPNQE(O-2-PhiPr)QK(Mtt)-Sieber resin (1) was synthesized by a manual solid phase peptide synthesis (SPPS) protocol using commercially available N-Fmoc protected amino acids, Sieber amide resin as the solid support and HBTU/HOBt as the carboxyl-group activating agents.
Pyro-T(Trt)S(Trt)GPNQE(O-2-PhiPr)QK(Mtt) -Sieber resin (2)
After the last Fmoc group was removal from the peptide-resin (1) with 20% piperidine in N,Ndimethylformamide (DMF), the resin was washed with 1-methyl-2-pyrrolidinone (NMP) and pyropheophorbide acid (Pyro-acid) was coupled to the N-terminal threonine of the peptide-resin (Pyro acid/HOBt/HBTU/peptide 3:3:3:1).The reaction was shaken under argon overnight at room temperature, following which the green resin was washed and dried to give Pyro- This peptide resin (2) was treated with 3% trifluoroacetic acid (TFA) and 5% triisopropylsilane (Tis) in dichloromethane (DCM) for 1 h at room temperature to cleave the peptide sequence from the Sieber resin and deprotect the Mtt group on the C-terminal Lysine. After removing the cleaved solid resin by filtration, the filtrate was concentrated and precipitated by adding anhydrous ether to give Pyro-TSGPNQEQK(ε-NH 2 )(3). It was further washed by ether and dried under high vacuum. A part of Pyro-TSGPNQEQK(ε-NH 2 ) (3) was purified by HPLC to obtain FAP-PP as positive control (without quencher moiety).
Pyro-TSGPNQEQK(BHQ3) (4)
The Pyro-peptide (3) (10mg, 6µmol) was dissolved in 200µL of anhydrous dimethyl sulfoxide (DMSO) with 1% of N,N-diisopropylethyl amine (DIPEA) and reacted with BHQ3-NHS (4.7mg, 6µmol, Biosearch Technologies, Novato CA, USA) for 3 h under argon. The reaction was stopped by precipitation with 2 mL ether, to give Pyro-TSGPNQEQK(BHQ3) (FAP-PPB, 4). This peptide was then purified by HPLC and identified by MALDI-TOF.
(2) FAP-P(C6)PB (5)
The synthesis protocol for FAP-P(C6)PB is similar to that of FAP-PPB with the difference of coupling Pyro(C6)-acid , instead of Pyro-acid. Figure 5A showed the structure of Pyro(C6)-acid.
O 2 generation assays in solution
PDT-generated 1 O 2 was quantified in solution by directly measuring its NIR luminescence at 1270 nm using an instrument that has been described before 4 . Briefly, 10 ns pulsed 524 nm laser excited the solution and the luminescence spectrum was sampled, after rejection of PS fluorescence, using a set of interference filters, with a high-sensitivity NIR photomultiplier module (H9170-45, Hamamatsu, USA) tube operating in the time-resolved single photon counting mode.
RESULT AND DISCUSSION

Cleavable activation mechanism
In PMB design, if the natural function of the choice of target is capable of cleaving chemical bonds, the PMB linker should be designed to be recognized and cleaved by the biomarker, such as short peptides cleavable by endoproteases, oligonucleotides cleavable by DNAses or RNAses, or phospholipids cleavable by phospholipases.
FAP-triggered PMB
In our previous study 2 , we have reported the MMP7-triggered PMB and its controlled PDT selectivity in cancer cells. Here we introduce a new PMB for targeting a different tumor-associated protease, fibroblast activation protein (FAP). FAP was found to be overexpressed in the stroma of 90% of malignant lung, skin, breast and colorectal tumors 5, 6 . The restriction of FAP expression in stromal fibroblasts and its total lack of expression in epithelial tumor cells or normal tissues, suggested the involvement of FAP in tissue remodeling 7 . FAP was further found to degrade gelatin and type I collagen 8 , implying its possible role in accelerating the degradation of extracellular matrix. Thus it helps a fast-growing tumor to invade the surrounding normal tissue. Therefore, FAP is an excellent target for PMB.
FAP is an endoprotease and has a very similar structure and enzymatic activity as APCE (an antiplasmin-cleaving enzyme) 9 . Therefore, a peptide sequence known as a APCE substrate 10 , "TSGPNQEQG", was selected to test as the FAP-cleavable linker. Using this linker to connect the Pyrobased PS and BHQ3-based quencher, we have synthesized a FAP-triggered PMB (FAP-PPB). The synthesis protocol is shown in Figure 2 .
To test whether the designed peptide linker can be cleaved specifically by FAP, the peptide sequence alone with an Fmoc protecting group on the N-terminal of TSGPNQEQK, Fmoc-TSGPNQEQK (Fmoc-FAP), was firstly used to check the FAP-triggered cleavage. For this assay we used murine FAP since it has very high homology to the human FAP (89% sequence identity) 11 and is easily available. As shown in Figure 3A , Fmoc-FAP was completely cleaved within 2 h ( Figure 3D ) and the MALDI-TOF spectrum of cleaved Fmoc-part confirmed that the specific cleavage site between P and N, the known cleavage site for APCE 9 (Figure 3 B) . This demonstrates that the TSGPNQEQK sequence is suitable as a linker for FAPtriggered PMB design.
After the linker was confirmed as suitable for FAP-triggered PMB design, FAP-PPB was tested for FAP cleavage. As shown in Figure 4A , the HPLC chromatograph showed that 95% FAP-PPB was cleaved after 24 h incubation with FAP at 37°C, generating two fragments with Pyro part at 33.5 min (RT= 33.5 min) and BHQ3 part at 27.88 min (RT=27.8 min). This specific cleavage was further confirmed by MALDI-TOF. The two fragments were identified as Pyro-TSGP-COO -(Mass calc. 873.39, found 872.10)
(1) (Figure 4D ), further confirming the FAP-mediated cleavage between P and N. However, the cleavage rate (95% cleavage in 24 h) is very slow, that probably because attachment of the bulky molecules, either Pyro or BHQ3, to the linker, makes the difficult for FAP to cleave linker.
To improve the cleavage rate, an modified FAP-triggered PMB, FAP-P(C6)PB, was synthesized by coupling a C6-linker modified Pyro (Pyro(C6)-acid , Figure 5A ) to the N-terminal of TSGPNQEQK sequence, thus Pyro and the peptide sequence was spaced by the C6-linker ( Figure 5B ).
To assess the influence of additional C6 linker between Pyro and the peptide linker on the FAPmediated cleavage, the cleavage rate of FAP-PPB and FAP-P(C6)PB was compared by real-time monitoring the fluorescence of FAP-PPB +FAP (100:1 molar ratio) and FAP-P(C6)PB + FAP (100:1 molar ratio) at 37°C ( Figure 6 ). It is validated that both FAP-PPB and FAP-P(C6)PB are cleaved by FAP and the In summary, we have developed a FAP-triggered PMB. The cleavage rate of this PMB should be further improved in future by spacing the BHQ-3 from the peptide or incorporating arginine amino acids to each end of the linker to improve the solubility.
Phospholipases-triggered PMB
Based on this cleavage activation approach, we recently developed a phospholipases-triggered PMB linker. As depicted in Figure 7 , there are three conjugation positions in this glycerol-based linker, R1, R2 and R3. A PS could be conjugated to one of these positions while one or two BHQ3 conjugating to others. This tunable design could distinguish between phospholipase PLA1, PLA2 or PLC/PLD activities.
By conjugated a Pyro-based PS on the position R2 and a BHQ3-based quencher on the position R3, We have validated that the Pyro fluorescence is quenched by 16-fold and could be primarily activated by PLC. In future, we will optimize the linker design to improve the cleavage specificity of phospholipases.
Openable activation mechanism
The target of PMB could also be a molecule that interacts strongly with a linker or a carrier, originally holding the dye and quencher in a close proximity, so that once these interact, the dye and quencher are forced apart and PDT efficacy of PMB is activated.
mRNA-triggered PMB (mRNA-PMB)
Tumor specific mRNAs are well known as important specific markers for cancer. Given that the hybridization of mRNA to its complementary oligonucleotide sequence by Watson-Crick base pairing is a highly selective and efficient process, antisence oligonucleotides (AS-ONs) have emerged as very attractive therapeutic agents. By taking advantage of the AS-ON sequence, we design a nucleic acid-based mRNAtriggered PMB (mRNA-PMB). As shown in Figure 8 , this mRNA-PMB consists of a single-stranded oligonucleotide as a linker which can form a stem-loop structure. Briefly, the loop is an AS-ON sequence complementary to mRNA specific for the target cancer cells. Two complementary arm sequences on either side of the loop sequence hybridize each other, thus forming the stem-loop structure. A PS and a quencher are attached to the end of each arm sequence respectively. In native state, the stem-loop constructed linker induced proximity of PS and Q make the mRNA-PMB photodynamic silent. In the presence of the tumorspecific mRNA, the loop sequence hybridizes with the mRNA, disrupting the hydrogen bonds of the stem and making the linker opened. The quencher hence is removed from the immediate vicinity of the PS. Upon irradiating with light, the PS emits fluorescence and generates cytotoxic singlet oxygen.
Using Pyro and CAR as PS-quencher pair, c-raf-1 mRNA as target molecule, we have synthesized a 30 bases-consisted mRNA-PMB, Pyro-30mer-CAR (P30C), with the middle 20 bases sequence as loop and 5 bases on each end respectively as two complementary arm sequences. The 1 O 2 luminescence count of P30C was measured and compared with P30 (Pyro with the RNA linker without quencher) and P30C incubated with the target RNA which is comprised of 20 bases, selected from the wide-type of c-raf-1 mRNA sequence, and complementary to the loop sequence of P30C. As shown in Figure 9 , P30C alone produced 15-fold less 
CONCLUSION
PMBs improve the PDT selectivity by controlling the ability of PS to produce 1 O 2 in response to specific cancer-associated biomarkers. They are inherently flexible and tunable in term of the choice of the target biomarkers and their corresponding linkers. In this report, we have developed three different linkers to make PMB switchable by FAP, phospholiase and a tumor-specific mRNA respectively. The versatility of the PMB design offers the ability to 'tailor' the PDT selectivity for personalized treatment and diagnosis of cancer. 
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